anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: DSFC (delayed subaponeurotic fluid collection) is a benign pathology associated with the first weeks of life and scarcely described in the literature. Normally characterized by a lack of trauma and/or cranial fracture, it is associated with a history of instrumental delivery and the use of fetal electrodes. Taking it in consideration in the differential diagnosis of neonatal scalp swelling becomes important. The objective of this work is to expand knowledge on this entity: history, clinical characteristics, diagnosis, and treatment.
METHODS: This article describes a new clinical case and conducts a systematic review according to the PRISMA criteria.
RESULTS: Sixty-seven cases are included, they are summarized in a table.
CONCLUSIONS: DSFC appears generally 15-16 weeks after birth. The diagnosis is mainly clinical, based on a history of instrumental birth, labor dystocia, or trauma, and with compatible symptoms and evolution. It may be supported by complementary tests such as ultrasound and or CT of the skull in doubtful cases. The treatment of choice is only conservative, and all cases resolve spontaneously and completely after an average of 4 weeks.
A protein which is used as a marker for diagnosing diabetic retinopathy is provided to diagnose diabetic retinopathy in tear of patients with diabetic retinopathy by increasing or decreasing the expression of the protein. A biomarker for diagnosing diabetic retinopathy comprises a protein of which expression is relatively increased in tear of patients with diabetic retinopathy. The protein of biomarker comprises: a DJ-1 protein which has trypsin lysis sequence of the sequence numbers 1 and 2, 24-26 kDa of molecular weight and 5.83-6.83 of pI value; and a beta 2-microglobulin (B2M) having 15-17 kDa of molecular weight and 5.27-6.27 of pI. The biomarker for diagnosing diabetic retinopathy also comprises a protein of which expression is relatively decreased in tear of patients with diabetic retinopathy. A agent for diagnosing diabetic retinopathy comprises the biomarker protein or antibody which specifically binds to its immunogenic fragment as an active ingredient. The antibody is monoclonal antibody.
Vasoplegic syndrome is a form of distributive shock that is characterized by low arterial pressure with reduced systemic vascular resistance and normal or elevated cardiac output that occurs in 5 to 25% of patients undergoing cardiac surgery. Patients with vasoplegic shock after cardiac surgery are at higher risk of organ failure, including acute kidney injury (AKI). Postsurgical AKI is associated with several adverse outcomes. Attempts to prevent AKI have largely been futile so far. Prior studies often started with the interventions after an AKI event, when a decline of kidney function (i.e. glomerular filtration rate) was already established. Application of norepinephrine is currently considered as the first-line therapy for vasoplegic shock, but all catecholamines have adverse effects, including myocardial ischemia and arrhythmias. In a recent observational trial, we demonstrated that there is a dysregulation in the renin-angiotensin-aldosterone system (RAAS) likely caused by a reduced angiotensin-converting enzyme (ACE) activity after cardiac surgery. Elevated renin levels identified patients at risk for AKI and were associated with cardiovascular instability and increased AKI rate after cardiac surgery. Furthermore, elevated renin levels could be used to identify high-risk patients for cardiovascular instability and AKI who would benefit from timely intervention with angiotensin II that could improve their outcomes. Therefore, the application of angiotensin II to treat a postoperative hypotension would mean a hormone substitution.Shock after cardiac surgery is associated with increased mortality. Cardiopulmonary bypass (CPB) represents a common clinical setting of sympathetic nervous system activation and cardiovascular instability. Vasoplegia is a form of distributive shock that is characterized by low arterial pressure with reduced systemic vascular resistance and normal or elevated cardiac output. It occurs in 5 to 25% of patients undergoing cardiac surgery. Patients with vasoplegia after cardiac surgery are at higher risk of organ failure, including AKI, and have an increased mortality rate and longer hospital length of stay.

Clinical trials focusing on septic patients suggest that AT-II is a potent vasopressor. However, no human data exist whether the application of AT-II in cardiac surgery patients with y hyperreninemia high-risk patients identified by renin levels (individualized approach) reduces kidney damage and improves kidney function after cardiac surgery.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to chemical-pharmaceutical industry, and deals with medication for internal application in form of tablets, in composition of which main active substance is mexidol. Pharmaceutical medication in form of tablet contains mexidol, lactose monohydrate, magnesium stearate and sodium carboxylmethylcellulose. Additionally pharmaceutical medication can contain collidone 30 (polyvinylpyrrolidone). Tablets are mainly covered with coating based on film-producing suspension Opadry II white. ^ EFFECT: elaboration of novel medication. ^ 3 cl, 3 ex
Extract of a fruit body derivative of Antrodia cinnamomeaobtained by providing a dried fruit body of Antrodia cinnamomea, extracting with ethanol at a specific temperature to obtain an acetic acid extract, concentrating the acetic acid extract to obtain a concentrated product, and separating the concentrated product with acetic acid ethyl ester and water to produce an acetic acid ethyl ester extract, is claimed. Independent claims are also included for: (1) Antrocamphin A for inhibiting the formation of nitric oxide and prostaglandin-E2; and (2) inhibiting the formation of pro-inflammatory molecules, comprising bringing the investigated object in contact with the extract or Antrocamphin A. ACTIVITY : Antiinflammatory. MECHANISM OF ACTION : Nitric oxide inhibitor; Prostaglandin-E2 inhibitor; Nitric oxide synthase suppressor; Cyclooxygenase-2 suppressor. The ability of the acetic acid extract (ACE 500) comprising lipopolysaccharide (5 g/ml) and the ACE (500 mg/kg) to inhibit the formation of nitric oxide was tested via injecting the ACE and lipopolysaccharide, respectively into mice (6). The result after anesthetizing with ether and decapitating the mice after 12 hours showed that the ACE 500 exhibited inhibition of the nitric oxide production of 8.79+- 0.11 compared to a negative reference group comprising lipopolysaccharide (5 g/ml), which exhibited the nitric oxide production of 37.79+- 1.87.
A device may receive data associated with a benefit manager organization. The data may relate to a performance of the benefit manager organization and hardware resources associated with the benefit manager organization. The device may process the data using a technique after receiving the data. The device may map the data to a benefit manager operating model based on processing the data. The benefit manager operating model may identify a functional area or a sub-area of another benefit manager organization. The device may perform an analysis of the data based on mapping the data to the benefit manager operating model. The device may identify a deficiency related to the performance of the benefit manager organization. The device may perform an action to positively impact the performance of the benefit manager organization based on identifying the deficiency. The action may reduce the deficiency.
The invention particularly discloses a probiotic active peptide, a probiotic active peptide composition and application thereof in preparation of a product with an anti-inflammatory effect. The amino acid sequence of the probiotic active peptide is shown as SEQ ID No.1 or SEQ ID No.2 or SEQ ID No. 3. The probiotic active peptide composition comprises probiotic active peptides with amino acid sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No. 3. The probiotic active peptide and the probiotic active peptide composition have anti-enteritis activity; simultaneously has the effects of resisting intestinal injury, relieving oxidative damage of intestinal epithelial cells or improving the antioxidation of the intestinal epithelial cells. Therefore, the probiotic active peptide and the probiotic active peptide composition have important application values when being used as effective components for preparing foods, dietary supplements or medicines with the effects of resisting enteritis, intestinal injury, relieving oxidative damage of intestinal epithelial cells or improving the antioxidation of the intestinal epithelial cells.
The present invention discloses medicine for treating symptoms of hemorrhage of bowel diseases, such as hemorrhoid, etc. The present invention is mainly composed of the following raw medicinal materials of 3 to 9 portions of cattail pollen, 1 to 4 portions of rhubarb, 10 to 30 portions of sanguisorba root and 3 to 9 portions of sophora fruit by weight. The medicine can be made into tablets, compositions, oral medicinal liquids, granules and capsules. The present invention has the efficiency of cooling blood for hemostasis, clearing away heat, loosing the bowels, dispersing swelling and relieving pain. The present invention is mainly used for curing various hemorrhage symptoms (wind-heat stasis symptom with syndrome of stagnant and jamming dampness-heat) of bowel diseases, and is especially suitable for curing disease symptoms, such as internal hemorrhoid of each stage, anus fissure, proctopolypus, etc. with hemorrhage as a main symptom. The present invention also discloses a method for preparing various dosage forms.
The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
PURPOSE: A choline phosphate like group containing compound or a manufacturing method thereof is provided to enhance moisture maintenance, anti-inflammation effects or anti-wrinkle effects. CONSTITUTION: A choline phosphate like group containing compound is represented by chemical formula(1). The choline phosphate like group containing compound is panthenyl phosphorylcholine represented by chemical formula (2). The choline phosphate like group containing compound is racemate. The optical activity of the choline phosphate like group containing compound is D form. A manufacturing method of choline phosphate like group containing compound comprises the following steps: synthesizing an intermediate represented by chemical formula 5; and synthesizing an intermediate containing phosphorylcholine represented by the chemical formula(1). The third amine represented by the chemical formula(6) is trimethylamine, dimethylmethanolamine or dimethylethanolamine.
Alpha-1 Antitrypsin (A1AT) is a major inhibitor of serine proteases and plays an important role in the lung as an inhibitor of neutrophil elastase. A1AT deficiency is associated with decreases in plasma A1AT levels and is associated with an increased risk for developing asthma, emphysema/COPD, and bronchiectasis. Much of the lung damage is thought to be caused by proteolytic damage from neutrophil elastase and other proteases.

ADVM-043 is an investigational gene therapy product (serotype AAVrh.10 vector) expressing human A1AT that is intended to deliver a functional gene to the liver of patients with A1AT deficiency. Study ADVM-043-01 will study up to 4 dose levels in up to 20 patients and assess the hypothesis that a single administration of an AAV vector expressing the human M-type A1AT (i.e., ADVM-043) to patients with A1AT deficiency is safe and results in persistent therapeutic levels of A1AT in blood and alveolar epithelial lining fluid (epithelial lining fluid is only to be collected in subjects who are dosed intrapleurally). The primary endpoint is safety, and changes in plasma A1AT levels at multiple time points up to 52 weeks after dosing. A prophylactic tapering corticosteroid regimen will be used to protect against potential vector induced transaminitis. Subjects will be followed for up to 52 weeks after dosing. Safety and efficacy data from the IV cohorts will be considered when determining whether to proceed to intrapleural administration. After completion of this study, subjects will be asked to enroll in a Long Term Follow Up study.
A drug management apparatus is provided. The drug management apparatus includes a drug storage and a processor. The drug storage includes a main body and a movable mechanism. The main body has a storage space used for drugs storage. The movable mechanism is disposed on the main body and provides a movable member which moves inside the storage space. The processor is coupled to the movable mechanism. The processor is configured to obtain physiological measurement data and control the movable mechanism according to the physiological measurement data. Accordingly, the convenience of taking drug could be improved.
PROBLEM TO BE SOLVED: To provide a medical image diagnostic system capable of improving efficiency in creating an image reading result.SOLUTION: A medical image diagnostic system includes a server device 500 and a medical image display device 400. The server device 500 includes a first creation part 511 and a second creation part 512. The first creation part 511 creates an object including a plurality of selection candidates based on an image reading request for medical image data, transmits the object and the medical image data to the medical image display device 400, and causes it to display them. The second creation part 512 creates an image reading result using the selection candidates received from the medical image display device 400. The medical image display device 400 includes a display control part 411 and a response part 412. The display control part 411 causes a display part 403 to display the object received from the server device 500. The response part 412 receives the selection of at least one selection candidate from the object that the display part 403 is caused to display, transmits the selected selection candidate to the server device 500, and responds.SELECTED DRAWING: Figure 1
OBJECTIVE: It has been suggested that diseases that may cause visual evoked potential abnormality, such as optic neuritis, may be associated with the coronavirus disease 2019. This study aimed to find out whether there are visual evoked potential abnormalities in coronavirus disease 2019 patients using pattern reversal visual evoked potential and flash visual evoked potential.
METHODS: Patients with a history of coronavirus disease 2019 (coronavirus disease 2019 patients) and controls were included in this prospective case-control study. This study was conducted in the Clinical Neurophysiology Laboratory of Adana City Training and Research Hospital. Individuals without visual impairment were included. Coronavirus disease 2019 patients were required to have clinical features consistent with previous acute infection and a positive nose swab polymerase chain reaction test. Visual evoked potential was applied to coronavirus disease 2019 patients between July 2020 and July 2021. Controls consisted of patients without a history of chronic disease who underwent a visual evoked potential study between June 2017 and June 2018 due to headache or dizziness. Pattern reversal visual evoked potential and flash visual evoked potential were applied to all participants. N75, P100, and N135 waves obtained from pattern reversal visual evoked potential and P1, N1, P2, N2, P3, and N3 waves obtained from flash visual evoked potential were analyzed.
RESULTS: A total of 44 coronavirus disease 2019 patients and 40 controls were included in the study. Age and gender were not different between the two groups. Pattern reversal visual evoked potential parameters were not different between the two groups. Right P2 latency was 114.4±21.1 and 105.5±14.7 ms in coronavirus disease 2019 patients and controls, respectively (p=0.031). Patients with P100 and P2 wave abnormalities were 6 (13.6%) and 13 (29.6%), respectively.
CONCLUSION: This study showed that there may be visual evoked potential abnormalities in coronavirus disease 2019 patients.
This case report describes a three-year-old male intact border collie diagnosed with canine papillomavirus type 1 (CPV-1+) oral papillomas resistant to standard-of-care. With time, he developed lesions consistent with squamous cell carcinoma. Malignant tumors were incompletely excised and treated with definitive external beam radiation therapy (45 Gy, 3 Gy × 15 daily). The remaining oral cavity received 27 Gy (1.8 Gy x 15 daily) to treat the disseminated oral papillomatosis. A temporary treatment delay of 2 weeks was instituted due to grade 3 mucositis. The patient remained in complete remission after 10 months from radiotherapy. No tumor recurrences were noted by the owners after >1 year from treatment.
In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
The invention discloses a traditional Chinese medicine composition for treating common cold due to wind-cold by virtue of a medicated bath. The traditional Chinese medicine composition consists of the following traditional Chinese medicines: 65 to 75 grams of raw ephedra, 45 to 55 grams of fineleaf schizonepeta herb, 45 to 55 grams of Chinese parsnip root, 45 to 55 grams of radix puerariae, 45 to 55 grams of mulberry leaves, 45 to 55 grams of chrysanthemum, 45 to 55 grams of white mulberry root-bark, 45 to 55 grams of cassia twig, 20 to 30 grams of scutellaria baicalensis and 20 to 30 grams of asarum. When the traditional Chinese medicine composition is used, the traditional Chinese medicines are placed in a pot, 1,500 millimeters of water is added, the mixture are decocted for 20 minutes, decoction is poured into a basin, and water is added to continuously decoct the dregs in the pot. Feet are fumed by the steam of the primary decoction, and are soaked after the temperature of the primary decoction is proper, secondary decoction can be added at any time to keep the temperature of the decoction, the feet are soaked for 20 to 30 minutes every time, and legs are better to be soaked in the decoction. The decoction can be reused, and is only require to be heated. The traditional Chinese medicines act on the fleshy exterior, local parts and wounds of the whole body, and are absorbed to run through channels, collaterals and blood vessels and reach the internal organs from the outside, thereby achieving effects.
An improved form of tumor necrosis factor (TNF) can be employed to regulate TNF channel activity. The identity of the amino acids which line the channel of the TNF molecule and which exert significant control over the activity of the channel are disclosed. The improved form of TNF includes amino acid substitutions, additions, and/or deletions, and/or chemically modified amino acid residues within the channel region for enhancing, diminishing, and/or modulating its channel activity within target membranes. The modified form of TNF is capable of trimerization and of achieving intimate contact with a target membrane containing one or more types of TNF receptor. Contacting target membranes with forms of TNF having modified channel activities can be employed to regulate the permeability and/or response of the target membrane. Greater control over the regulation of the permeability and/or response of target membranes can be achieved with modified forms of TNF as compared to unmodified TNF.
Background: There has been arise in a number of patients requiring long term ventilation both in the in-hospital as well as the out-of-hospital setting. Despite this, little is known about the subsequent political course of this patients following hospital discharge.

Interventions: This is an observational prospective study over a period of one year in a sample of 50 to 70 invasively ventilated patients living either in a nursing home specialized in the care of ventilated patients or at home. Protocol had been developed containing 20 suspected emergency incidences in respiratory care. The nursing staffs are instructed about the study and how to complete the protocol. The protocol was placed at each patient and every time an emergency occurred, the nursing staff registered the incidence. If an emergency fulfils more than one criterion in the protocol, every applicable criterion was marked. The data will be analyzed using non-parametric descriptive statistics.
Congenital heart disease (CHD) accounts for nearly one-third of all major congenital anomalies, with atrial septal defect (ASD) and ventricular septal defect (VSD) being the most common forms of simple CHD, which involve a large number of susceptibility genes. However, despite extensive research, the etiology of ASD and VSD remains unclear. Yunnan Province has advantages in exploring CHD pathogenesis due to its unique genetic background. Therefore, we aimed to evaluate the association between single nucleotide polymorphisms (SNPs) of genes and susceptibility to simple CHD in a specific population by means of a case-control study. A total of 337 healthy controls and 767 patients with simple CHD (501 ASD and 266 VSD) from China were recruited. Candidate SNPs were identified through whole-genome sequencing of pooled CHD patients and controls (pool-seq). Genotyping from 1,104 samples was performed, and stratified analysis was conducted to explore the association between positive SNPs and CHD subtypes. χ2 tests and logistic regression were used to analyze the relationship between each SNP and simple CHD. Of 11 SNPs identified, SOD2 rs62437333 (P = 0.005) and POU5F1 rs3130504 (P = 0.017) showed differences between the control and ASD cohorts. In the dominant inheritance model hypothesis, rs62437333 allele C carriers had increased ASD (odds ratio (OR) = 2.04, P = 0.005) and combined simple CHD risk (OR = 2.33, P = 0.012) compared to DD genotype, while rs3130504 allele C carriers had increased ASD risk (OR = 1.121, P = 0.045) compared to DD genotype.